Dr. Nancy Reid, MHA, DMSc, PA-C, DFAAPA
Purpose: The purpose of this article is to review the effectiveness of sacubitril/valsartan in improving left ventricular systolic function as compared to cardiac resynchronization therapy (CRT) in adults with cardiomyopathy.
Method: Using the search engine PubMed, the terms sacubitril/valsartan, cardiac resynchronization therapy, and combined sacubritil/valsartan and cardiac resynchronization therapy were searched. Sixteen relevant articles were identified and will serve as the basis for the literature review.
Results: Evidence-based research has shown sacubitril/valsartan to be effective in increasing left ventricular systolic function. However, further research is needed to determine if it is superior to cardiac resynchronization therapy.
Conclusion: Traditional treatment for cardiomyopathy has included the use of beta-blockers, diuretics, and angiotensin-converting enzyme inhibitors along with cardiac resynchronization therapy. Sacubritil/valsartan has received approval from the Food and Drug Administration for the treatment of cardiomyopathy. Studies have reported the effectiveness of sacubitril/valsartan however it is not known if it is superior to cardiac resynchronization therapy.
Keywords: cardiomyopathy, cardiac resynchronization therapy, sacubitril/valsartan
Hardin S. Treatment of Cardiomyopathy. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.